Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
ProstaDrops is a traditional herbal medicinal product developed and marketed by PannonPharma for the symptomatic treatment of benign prostatic hyperplasia (BPH). The formulation is an oral solution (drops) containing a synergistic combination of plant extracts, including small-flowered willowherb (*Epilobium parviflorum*), goldenrod (*Solidago virgaurea*), nettle root (*Urtica dioica*), pumpkin seed (*Cucurbita pepo*), and poplar bud (*Populus nigra*). These botanical components act together to provide anti-inflammatory, diuretic, and spasmolytic effects. The product is intended to alleviate lower urinary tract symptoms (LUTS) such as frequent urination, nocturnal urgency, and difficulty in bladder emptying associated with prostate enlargement. It is registered in Hungary as a medicinal product with established therapeutic use.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on ProstaDrops.